Among these, cemiplimab, an anti-PD-1 monoclonal antibody, has become the first systemic immunotherapy approved for patients with unresectable or metastatic cSCC, demonstrating favorable efficacy and safety profiles in both clinical trials and real-world settings [10,11]. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.